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Abstract 
The formation of protein coronas on nanoparticles (NP) has been investigated almost exclusively in 
serum, despite the prevailing route of exposure being inhalation of airborne particles. In addition, an 
increasing number of nanomedicines, that exploit the airways as the site of delivery, are undergoing 
medical trials. An understanding of the effects of NPs on the airways is therefore required. To 
further this field, we have described the corona formed on polystyrene particles with different 
surface modifications and on titanium dioxide particles when incubated in human bronchoalveolar 
lavage fluid (BALF) from patients with protein alveolar proteinosis (PAP). We show, using high-
resolution quantitative mass spectrometry (MSE), that a large number of proteins bind with low copy 
numbers but that a few ‘core’ proteins bind to all particles tested with high fidelity, averaging the 
surface properties of the different particles independent of the surface properties of the specific 
particle. The averaging effect at the particle surface means that differing cellular effects may not be 
due to the protein corona but due to the surface properties of the nanoparticle once inside the cell. 
Finally, the adherence of surfactant associated proteins (SP-A, B and D) suggests that there may be 
interactions with lipids and pulmonary surfactant (PSf), which could have potential in vivo health 
effects for people with chronic airway diseases such as asthma and chronic pulmonary obstructive 
disease (COPD), who have increased susceptibility toward other respiratory diseases. 
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Introduction 
Epidemiological studies have demonstrated a link between airborne particulate matter and 
increased morbidity and mortality (Laden et al. 2000; Laden et al. 2006; Pope et al. 2004; Samet et 
al. 2000). In light of this and increased usage of nanoparticles (NPs) in modern composite materials, 
including application of nano-sized therapeutics (Schütz et al. 2013), numerous studies are aimed at 
understanding the fate and cellular toxicity of nanoparticles (NPs <100 nm) (Commission 2011). 
Inhaled NPs may reach the lower lung alveolus (Oberdörster et al. 2005) where the particles can 
interact with pulmonary surfactant (PSf) (Schleh & Hohlfeld 2009), a single molecule layer of 
predominantly (90%) phospholipids and proteins (10%) (Pérez-Gil 2008), before passing into the 
underlying hydrophase. In biological media, NPs rapidly become coated in proteins, which form a 
corona around their surface (Cedervall et al. 2007) and thus previously biologically inert particles 
may acquire a biological identity. 
Surfactant associated proteins and lipids can bind to NPs (Kendall et al. 2012; McKenzie et al. 2015; 
Kendall 2007; Ruge et al. 2012). Therefore, there is potential for NPs to have an in vivo effect on 
surfactant function. This is further evidenced through in silico modelling of surfactant function and 
NP translocation through the surfactant monolayer (Hu et al. 2013; Choe et al. 2008). Metallic NPs 
may reduce the surface activity of model surfactant (Bakshi et al. 2008), through mechanisms likely 
to be associated with adsorption of PSf components such as proteins (Fan et al. 2011; Dwivedi et al. 
2014). 
To date, many studies have investigated NP-protein interactions in serum, for which comprehensive 
lists of proteins that adsorb to the NP corona have been published (Tenzer et al. 2013; Cedervall et 
al. 2007; Schäffler et al. 2013) and it may be possible to predict the cellular fate of NPs from this data 
(Walkey et al. 2014). However, there remains no analysis or identification of proteins bound to NPs 
in the context of the lung. This is likely due to the abundant and convenient availability of serum 
compared with a lung-related bio-fluid, for nanoparticle-protein kinetic studies. 
Patients with pulmonary alveolar proteinosis (PAP) (Seymour & Presneill 2002) have reduced 
recycling and consequent build-up of PSf within their alveoli. The lipo-proteinaceous material may 
be removed through whole lung lavage which is typically performed during a single procedure, and 
can result in approximately 12-15 L of material per patient (Strong et al. 1998; Shah 2000). This 
material differs from ‘healthy’ lung through increased levels of lipids and surfactant protein A (SP-A) 
(Honda 1993) and SP-D (Honda et al. 1995) with a 10-fold and 7-fold increase respectively. The 
proportion of SP-A to the total protein is similar between PAP and healthy control, suggesting that 
whilst the fluid may be more concentrated for lipids and proteins, the proportions of these proteins 
remains constant (Honda 1993). Therefore, we believed that this media would be a useful source of 
pulmonary material for investigating NP-protein interactions within the context of the pulmonary 
system. 
Using high resolution, quantitative mass spectrometry (MSE), we describe the proteins from BALF 
binding to 3 polystyrene (PS) NPs with different surface modifications – aminated (aPS), 
carboxylated (cPS) and unmodified (uPS) – and one metal (TiO2) and a time study of the corona 
formed around aPS and cPS. The research has demonstrated that only a few proteins bind to the NPs 
with high fidelity and do so regardless of particle surface functionality. Furthermore, we have 
observed the adherence of surfactant associated proteins (SP-A, SP-B and SP-D) binding to the 
surface of the particles, suggesting a mechanisms through which inhaled NPs may affect health.  
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Methods 
For full method descriptions, see Supplementary Methods. 
Nanoparticles 
100 nm polystyrene (PS) were purchased from Polysciences Incorporated (Germany) and TiO2 
particles from Evonik Industries (UK). Particles were stored at 4oC and were handled in a class 2 
safety cabinet to maintain their sterility. 
Dynamic Light Scattering and Zeta Potential 
Hydrodynamic diameter and zeta potential (ZP) measurements were acquired at 37OC. 5 cm2 of 
nanoparticles were suspended in 1 mL of PBS. We were not able to take comparable measurements 
in BALF due to health and safety concerns about the risk of contamination of the apparatus from 
unscreened human material. 
Cell Culture and Cellular Assay 
A549 cells were treated with BALF-coated or untreated NPs for 24 hours. Mitochondrial activity was 
assessed by the cells ability to reduce MTT to insoluble formazan, the concentration of which was 
determined by absorbance at 550 nm. 
Bronchoalveolar Lavage Fluid and Corona Formation 
Bronchoalveolar lavage fluid (BALF) was acquired by therapeutic lung lavage from a patient suffering 
pulmonary alveolar proteinosis (PAP) with informed consent under approved ethics (NRES reference 
10/H0504/9). Approximately 13 L was acquired from a single patient and the first 4 L were pooled 
and aliquoted prior to freezing at -20oC. Before incubating the particles, the BALF was defrosted and 
briefly centrifuged at low speed to pellet large agglomerates and cellular debris before being 
centrifuged for 30 minutes at 10,000 x g to remove smaller agglomerates. 
For LC-MS analysis of the proteins corona, 50 cm2 of particles were incubated in 20 mL 
(approximately 5 mg total protein) of BALF for 15, 30, 60 or 120 minutes. For cellular assays, 500 cm2 
of particles were suspended in 30 mL of BALF for 60 minutes. Particle-BALF mixtures were 
centrifuged at 10,000 x g for 30 minutes to pellet the NPs, which were either washed 5 times with 1 
mL phosphate buffered saline, centrifuging for 15 minutes at 17,000 x g (for corona analysis) or 
diluted to relevant concentrations by serial dilution in serum-free media for cellular assays. 
LC-MSE 
Particles were run into an SDS PAGE gel for 10 minutes to elute the proteins. Each lane was then 
excised and cut into approximately 1 mm3 pieces and in gel reduction, alkylation and tryptic 
digestion performed. Peptides were extracted using 1% (v/v) formic acid, and 2% (v/v) acetonitrile in 
25 mM ammonium bicarbonate buffer. Samples were analysed by LC-MSE in resolution mode (Acuity 
UPLC M-Class, Synapt G2S, Waters) over a 30 minutes gradient of acidified (0.1% v/v formic acid) 
acetonitrile (3-40%).  
Protein Identification, Bioinfomatics and Statistics 
Database searching and quantification was performed in ProteinLynx Global Server version 3.0 
(Waters), searching against human SwissProt (UniProt). Protein characteristics were extracted from 
ProtParam (ExPAsy).  
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Results 
 
Particle Characterisation 
Nanoparticles were thoroughly characterised by dynamic light scattering, electron microscopy and 
atomic force microscopy . Since agglomerated particles were not monodispersed, as is assumed by 
DLS, we have reported their size by ‘number’ (for z-averages, see supplementary table ST1). All 
particles increased in size following incubation in BALF. Both aPS and TiO2 particles formed large 
agglomerates in BALF (approximately 90 % and 439 % increase in size, respectively, by TEM), 
whereas cPS and uPS were more stable (supplementary table ST2). Since size was variable 
depending on method used to measure them and their suspension media, we used 100 nm 
(manufacturers label size) for surface area calculations of the polystyrene and 14.09 nm for TiO2. For 
all particles, zeta potential was negative, with aPS least negative, followed by uPS, cPS and TiO2 (-
11.5mV, -17.07, -19.73 and -22.7mV respectively) in PBS (pH 7.4). Owing to the agglomeration of aPS 
and TiO2 in BALF, we incubated the particles in large volumes (20-30 mL) of BALF to minimise the 
agglomeration. 
Particle toxicity was determined following cellular exposure to BALF-incubated or non-incubated 
particles at a range of concentrations for 24 hours (Figure 1). Both BALF coated and uncoated aPS 
particles decreased the reduction of MTT in living cells when added at high concentrations. 
Uncoated particles caused a statistically significant decrease by 100 cm2/mL whereas uncoated 
particle did not reach significant levels (Figure 1A). The addition of uncoated cPS particles caused a 
large increase in absorbance, whereas coated particles caused no deviation from untreated cells 
(Figure 1B). Uncoated uPS particles also caused a statistical increase, whereas there was no change 
when the particles had been pre-incubated in BALF (Figure 1C). In contrast, TiO2 particles caused no 
effect when uncoated, however, BALF-incubated particles caused an increase at concentrations of 1 
cm2/mL and below. It was observed that at low concentrations (0.01-1 cm2/mL), there was an 
increase in mitochondrial activity as observed by higher levels of insoluble fomazan. Preliminary 
experiments were performed showing no effect of the particles on MTT reduction, nor any effect of 
BALF at 1% (v/v) concentration (data not shown). 
Bronchoalveolar Lavage Fluid 
The protein concentration of BALF was determined after a freeze thaw cycle and after centrifugation 
at 10,000 x g for 30 minutes to be approximately 251 µg/mL. After the same treatment, 
phospholipid content was determined to be below the detectable range of the assay (< 10 µg/mL). 
Protein Corona 
As different modifications can lead to different cellular effects, we wished to determine if this was 
also true for the proteins that bound to the surface of the particles. We determined, by SDS PAGE 
and BSA assay, that 5 washes were sufficient to remove non-bound proteins (Supplementary figure 
S1). 
Corona proteins from both aPS and cPS particles, incubated for 15, 30, 60 or 120 minutes were 
identified and quantified to gain an insight into the dynamics of protein-particle interactions on a 
time scale relevant in vivo (Supplementary File SF1 and SF2). The corona of TiO2 and uPS particles 
were also analysed after 60 minutes incubation in BALF (SF3). Proteins were normalised by dividing 
each sample by the sum of proteins (fmol) present in at least 90 % of all samples and identifications 
were accepted if they were detected in at least two repeats of a single time point (i.e. a subsequent 
identification of a bound protein in only 1 repeat was allowed provided at a different time point it 
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was detected in at least 2 repeats). Quantifications were only accepted if they were present in at 
least 2 repeats for each individual time points. 
The number of particles per molecule (calculated by dividing the number of molecules 
(mols*Avogadro’s number) by the number of particles) were consistant for cPS particles over the 
time course analysed, with an average of 400 protein molecules per particle (supplementary figure 
S2A). The number of molecules per particle for aPS averaged at 517, but, unlike cPS, was not a 
constant value, peaking at 30 minutes before dropping at 60 and 120 minutes. There was, however, 
large variation at 30 and 60 minutes, suggesting that the evolution of the corona may be 
changeable. When incubated for 60 minutes, carboxylated particles bound statistically fewer 
molecules than aPS or uPS (P = 0.006 and 0.042, respectively), TiO2 bound more molecules, although 
not statistically so (supplementary figure S2B). Aminated and carboxylated polystyrene particles and 
TiO2 particles bound similar numbers of molecules (aprox. 700) despite there being orders of 
magnitude difference in their sizes.  
The protiens binding to aPS and cPS particles were investigated over time. There were 34 and 32 
proteins detected that were common to all time points for aPS and cPS respectively (Figure 2), 
however, over time, both changed, with unique proteins being detected at all time points for aPS 
particles and at 30 minutes and 120 minutes for cPS particles. Of the proteins shared at all time 
points, 16 were quantified for aPS and cPS. These proteins changed very little over time and in 
general were present in high abundance on the particles (Figure 2C and D). 
To determine if the proteins were binding in a concentration-dependant manner – i.e. if the most 
abundant proteins in BALF were the most abundant proteins bound to the particles, BALF was also 
analysed by LC-MSE (SF4). The distribution of BALF proteins identified were ordered by their 
abundance, with the overall top 20 proteins found bound to the particles highlighted in red (Figure 
3). This showed that the most abundant proteins in the corona were not necessarily the most 
abundant in BALF and this was the case for all particles. Furthermore, there was high conservation of 
the corona at each time point for aPS and cPS (Figure 3A and B). Not all the proteins detected on the 
particles were identified in BALF, showing that proteins present in low amounts in bodily fluids can 
become concentrated on the particles. This suggests that there might be a physiochemical feature of 
the proteins driving their adhesion to the particles and vice versa. 
We investigated various properties of the bound proteins bioinfomatically, weighting by their 
abundance (Figure 4). The bound proteins were, in general, small (< 80 kDa), hydrophilic and acidic 
with little change in the average characteristics over the time course or between particles, although 
aPS particles bound proteins with a slightly higher GRAVY score (hydophobic). Principle Component 
Analysis (PCA) analysis of the unique proteins bound to each particle at 60 minutes was not able to 
discriminate between the particles based on their physical characteristics (data not shown).  
It was evident that the protein corona is relatively dynamic over time and cluster analysis grouping 
proteins by binding-pattern, identifying four distinct groups for aPS (Figure 5A) and cPS (Figure 5C).  
The physiochemical properties of the bound proteins were plotted using a PCA analysis which was 
then coloured according to the cluster the protein conformed to. This analysis did not highlight any 
relationship between their biophysical characteristics and their binding moiety.  
There were differences in the identity of the bound proteins between aPS and cPS over time (Figure 
2A and B) and all particles (SF1, 2 and 3) that was not reflected in the bioinfomatic data. This could 
be due to skewing by the abundant proteins. On average, less than 1% of the bound protein at any 
time point accounts for 20% of the total proteins present, and 20% of the bound proteins account 
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for 60 % of the total protein corona (Figure 6). Over time, the distribution of proteins bound to aPS 
particles changed very little, whereas for cPS particles, after 60 minutes, the proportion of protiens 
changed such that the percetage of proteins responsible for 80% of the total bound protein 
increased from 50% to 60%. Furthermore, there is strong conservation between the top 5-10 
proteins bound to aPS (Table 2) and cPS (Table 3) over time as well as to all particles (Table 1). 
 
Discussion 
Zeta potential readings of these particles were all less than 0 mV. Even for aPS particles that carry a 
positively charged functional group, the overall charge was negative, suggesting a low concentration 
of surface groups. Since the zeta potential of all the particles was quite close, any differences 
observed in the protein corona between PS particles are probably not a consequence of surface 
charge, but due to the functional groups. 
We identified a number of intracellular proteins from BALF which we would not expect to be present 
in a healthy lung and may be a result of mechanical agitation of lung tissue whilst acquiring the 
lavage. The presence of serum proteins suggests some degree of leakage into the lung from the 
underlying vasculature which it is likely also a common in vivo occurrence (Ward et al. 1997), 
although may also be exacerbated by mechanical agitation. 
Lactose dehydrogenase (LDH) and MTT assays are commonly performed to assay the toxicity of NPs. 
It has been observed by ourselves (e.g. Table 1) and Kendall et al. (Kendall et al. 2015) that LDH 
binds to particles and therefore could interfere with this assay. For this reason, we used the MTT 
assay, which is a measure of mitochondrial activity, to investigate particle toxicity (Weyermann et al. 
2005; Mosmann 1983). It has been observed across the literature that cationic particles, including 
polystyrene, are toxic to cells (Wang, Yu, et al. 2013), as observed similarly here with aPS particles 
(Figure 1A), where coating the particles decreased, but did not oblate their toxicity. Similar 
observations were made for cPS and uPS particles, where coating them with BALF decreased any 
differences in cellular activity between exposed and non-exposed particles. Given the increase was 
present at very low concentrations, we hypothesised that this increase could be due to a secreted 
factor in response to particulate exposure that may propagate an energy-dependent reaction, such 
as an inflammatory mechanism, within the cells. We therefore investigated a number of pro-
inflammatory cytokines by quantitative-PCR, but found no increased levels of mRNA for interleukin 
(IL)-4, IL-6 or tumour necrosis factor receptor 1 (data not shown). When coated in BALF, there was 
no change in cellular response for either cPS or uPS, suggesting that these particles were biologically 
inert to A549 cells, which may be true in vivo, or the concentration of the particles used in the assay 
was below what is required for an acute inflammatory response from this cell line. TiO2 particles did 
not have any effect on mitochondrial activity when they were uncoated, however, there was an 
increase in insoluble formazan of approximately 50% at low concentrations for BALF-coated, 
showing different behaviour from cPS and uPS particles. 
In vivo, particles become rapidly coated in proteins and lipids, and this process has been extensively 
studied in serum and media (Kendall et al. 2015). The primary route of exposure to airborne particles 
is due to inhalation and therefore studies in serum may not be relevant to environmental (pollutant) 
or inhaled nanotherapeutics (Wittgen et al. 2007). Therefore, we investigated the protein corona of 
NPs in BALF, which contains aqueous material from the lining fluid of pulmonary alveoli. Frequently, 
descriptions of protein coronas do not contain quantitative information of individual proteins and 
therefore analysis of the protein characteristics of the NP corona does not account for individual 
proteins present in high abundance. We have described the NP corona using high resolution MS to 
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obtain quantitative information that we have used to weight the particle descriptions, thereby 
describing a more accurate representation of the particle corona. 
The number of proteins bound to the particles was variable over time, particularly for aPS particles, 
(supplementary figure S2) upon which the number of proteins varied between 300 and 1000 per 
particle, suggesting highly dynamic binding kinetics. As discussed later, a relatively small number of 
proteins account for a large percentage of the corona and therefore this variability may be dictated 
by low abundance proteins. The TiO2 particles bound a similar number of proteins per particle 
compared with large polystyrene NPs despite being approximately 7x smaller and therefore having 
in the order of 49x less surface area per particle. The size of TiO2 NPs, as determined by TEM, was 
approximately 14 nm in PBS, however, by hydrodynamic diameter this was measured at 186 nm, 
suggesting agglomeration in solution. Therefore, it is possible that the number of particles present in 
the TEM samples was an underestimation, the variation in size making the calculation error prone 
for TiO2 (the polystyrene particles were more homogenous and therefore the number of particles is 
more reliable for these particles). 
There were few differences in the corona between any of the particles at any time points (Figure 4) 
and therefore it is unlikely that the protein corona formed within the lung would predict cellular 
uptake as reported elsewhere (Walkey et al. 2014). The proteins tended to be acidic and hydrophilic, 
although BALF may be enriched for such proteins as it is obtained using aqueous saline solution. 
There was conservation between the most abundant corona proteins, not only through time, but 
also between different particles (Table 1-3), suggesting that there is a small subset of proteins that 
dominate the protein corona. We investigated the composition of BALF to see if they bound through 
a concentration dependant manner, or if there could be a bio-physical attraction driving their 
adherence. The most abundant proteins on the corona were not necessarily the most abundant in 
BALF (Figure 3) although they tended to be amongst the top 50% of BALF-proteins. Not all of the 
proteins identified on the particles were identified in BALF alone, which suggests an enrichment of 
low abundance proteins on the particle surface (Bantscheff et al. 2007). The Vroman theory of 
protein exchange at hydrophobic surfaces, where high abundance, low affinity proteins are be 
exchanged over time for more strongly adherent but lower abundance proteins (Vroman 1962; 
Vroman & Adams 1969), has been applied to NP-protein interactions (Casals et al. 2010; Jung et al. 
2003). In part, our data supports this, since we see some proteins that are in high abundance in BALF 
also on the particles, but, analysis over time showed that these proteins were not exchanged. It has 
been demonstrated in serum that a stable corona can be formed in under 2 minutes (Dobrovolskaia 
et al. 2014; Tenzer et al. 2013). Our data shows that after 15 minutes, there is very little change in 
most of the protein bound to the particles, but there is change in the lower abundance proteins. 
Furthermore, clustering analysis demonstrated that there was not simply an on-off exchange of 
proteins but a number of distinct modalities and that protein binding could not be predicted based 
on their physiochemical properties . This finding may not be surprising when considering the scale 
between the nanoparticle and a protein. SP-A, one of the most abundant protein identified is 
approximately 40 nm in length and therefore is similar size to the PS and TiO2 particles used here. 
Therefore it is unlikely that the affinity of single functional groups will contribute greatly to the 
binding of the protein, rather the avidity of the particle surface. 
Since the NPs coronae are similar the effects on MTT reduction may be independent of the NP 
corona (Ehrenberg et al. 2009), in keeping with lysosomal-bursting hypothesis of cationic particle 
toxicity (Bexiga et al. 2011; Wang, Bexiga, et al. 2013). 
Bronchoalveolar lavage fluid is a mixture of lipids and proteins, therefore lipids maybe binding at the 
particle surface. The concentration of phospholipids, the predominant lipid species (Pérez-Gil 2008) 
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was determined to be <10 µg/mL, therefore protein was in large excess in comparison. That said, 
proteins known to interact with pulmonary lipids, such as SP-A, SP-B (Table 3) and SP-D (SF1) were 
found on the particles’ surface. SP-A and SP-D have been shown to bind to NP particles and affect 
their phagocytosis (McKenzie et al. 2015; Kendall et al. 2012). 
Here we show that the particles may bind these proteins in vivo. In particular, SP-A was present in 
high abundance on all particles. SP-A has multiple functions in innate immunity, PSf spreading and 
recycling (Kishore et al. 2006). SP-B, which was also observed to bind to NPs is a hydrophobic protein 
that interacts and assists spreading of PSf to maintain low surface tension (Schürch et al. 2010). 
Hence, sequestering of these surfactant proteins could have an influence of the surface tension 
lowering properties of surfactant. Furthermore, as discussed in the introduction, airborne NPs have 
been shown to have a detrimental effect on mortality, particularly amongst people with respiratory 
diseases (Kendall & Holgate 2012; Mackay et al. 2016). Mice made deficient for SP-A or SP-D have 
impaired surfactant metabolism and substructures (Korfhagen et al. 1998; Botas et al. 1998) and an 
impaired innate immune defence against bacterial and viral infections (Korfhagen et al. 1996; Pastva 
et al. 2007). 
At the air-liquid interface of the lung, PSf is a barrier to nanoparticle entry into the hydrophase. 
Nanoparticles can/must pass through this before reaching the hydrophase beneath (Choi et al. 2010; 
Hu et al. 2013). Particles have been shown to bind to lipids from this layer (Kendall 2007; Ruge et al. 
2012; Gonzalez et al. 1991) therefore inclusion of this layer is essential for a full description of 
nanoparticle-interactions with pulmonary fluids (Schleh et al. 2013). The BALF used throughout 
these experiments contained trace lipids species that could be identified by mass spectrometry (data 
not shown) and we observed the binding of proteins known to interact with PSf lipids. Nanoparticles 
have been shown to affect the functioning of PSf monolayers in vitro (Beck-Broichsitter et al. 2011; 
Dwivedi et al. 2014) and in silico (Hu et al. 2013; Lin et al. 2014), therefore future work would benefit 
from including a full description of the lipid corona. 
The BALF used was taken from patients with pulmonary alveolar proteinosis (PAP), a disease 
characterised by a reduction in clearance of PSf and consequently is rich in lipids and surfactant 
associated proteins (Seymour & Presneill 2002; Shah 2000). The presence of SP-A as a dominant 
protein on the particles’ surface may be as a consequence of its exaggerated abundance in PAP-
BALF, in which it is known to be high. However, in the analysis of BALF only, it was only the 50th most 
concentrated protein detected (Figure 3, Q8IWL1). Therefore there may also be significant binding 
of SP-A in non-PAP BALF, particularly as it is profuse in PSf. 
Conclusion 
A nanoparticle-surface corona forms quickly and stably following their incubation in BALF. Few 
proteins are bound in very high abundance on the surface, but those that are, are conserved over 
time and between particle types. The binding of proteins is independent of particle functionalisation, 
such upon inhalation, nanoparticle surfaces will become averaged, regardless of their intrinsic 
properties. We have detected the presence of PSf lipids binding to the surface of the particles (data 
not shown) that may further abrogate the intrinsic characteristics of the particle; this is currently 
under further investigation. We observe that there is a potential for pathological effects due to 
binding of surfactant-associated proteins and lipids to the particle surface.  
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 aPS 60min cPS 60min uPS 60min TiO2 60min 
1 Actin, cytoplasmic 1 Pulmonary surfactant-
associated protein A1 
Actin, cytoplasmic 1 Pulmonary surfactant-
associated protein A1 
2 L-lactate dehydrogenase A-
like 6A 
Actin, cytoplasmic 1 Pulmonary surfactant-
associated protein A1 
Actin, cytoplasmic 1 
3 Pulmonary surfactant-
associated protein A1 
L-lactate dehydrogenase A-
like 6A 
Serum albumin L-lactate dehydrogenase A-
like 6A 
4 Heat shock cognate 71 kDa 
protein 
Serum albumin Heat shock cognate 71 kDa 
protein 
Alpha-actinin-4 
5 Ezrin Moesin Moesin Moesin 
6 Moesin Annexin A2 L-lactate dehydrogenase A-
like 6A 
POTE ankyrin domain 
family member E 
7 Annexin A2 Alpha-enolase Alpha-actinin-4 Annexin A2 
8 Serum albumin 14-3-3 protein zeta/delta POTE ankyrin domain 
family member E 
Ras-related protein Rab-8A 
9 Alpha-actinin-2 Alpha-actinin-4 Annexin A2 Serum albumin 
1
0 
Dihydropyrimidinase-
related protein 2 
Ig alpha-1 chain C region Dihydropyrimidinase-
related protein 2 
Keratin, type II cytoskeletal 
8 
Table 1: Top 10 Proteins After 60 Minutes. Top 10 most abundant proteins bound to each particle 
after 60 minutes of incubation in BALF. Proteins with a grey back ground were identified on all 
particles. 
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# aPS 15min aPS 30min aPS 60min aPS 120min 
1 Pulmonary surfactant-
associated protein A1  
Actin_ cytoplasmic 1  Actin_ cytoplasmic 1  Pulmonary surfactant-
associated protein A1  
2 Actin_ cytoplasmic 1  Pulmonary surfactant-
associated protein A1  
Pulmonary surfactant-
associated protein A1  
Actin_ cytoplasmic 1  
3 Protein tweety homolog  Protein tweety homolog  Protein tweety homolog  DNA repair protein RAD50  
4 Moesin  Beta-actin-like protein 2  Beta-actin-like protein 2  Moesin  
5 Serum albumin  Moesin  Keratin_ type II cyt POTE ankyrin domain 
family member E  
6 Guanine nucleotide-
binding protein G(s) 
subunit alpha isoforms 
XLas  
Serum albumin  Moesin  Serum albumin  
7 Mucin-1 subunit alpha  Coiled-coil domain-
containing protein 167 
(Fragment)  
Keratin_ type I cyt Terminal uridylyltransferase 
4  
8 Annexin A2  Annexin A2  Annexin A2  Guanine nucleotide-binding 
protein G(s) subunit alpha 
isoforms XLas  
9 HLA class II 
histocompatibility 
antigen_ DRB1-1 beta 
chain  
Myosin-14 Serum albumin  Pulmonary surfactant-
associated protein B  
10 Chloride intracellular 
channel protein 1  
Beta/gamma crystallin 
domain-containing protein 
3  
Keratin_ type I 
cytoskeletal 9  
Sodium-dependent 
phosphate transport 
protein 2B 
Table 2: Top 10 Proteins on aPS Particles.Top 10 most abundant proteins at each time point for aPS 
particles. Proteins with grey back ground were identified at all time points. 
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 cPS 15min cPS 30min cPS 60min cPS 120min 
1 Pulmonary surfactant-
associated protein A1  
Pulmonary surfactant-
associated protein A1  
Pulmonary surfactant-
associated protein A1  
Pulmonary surfactant-
associated protein A1  
2 Actin_ cytoplasmic 1  Actin_ cytoplasmic 1  Actin_ cytoplasmic 1  Actin_ cytoplasmic 1  
3 POTE ankyrin domain 
family member E  
Pulmonary surfactant-
associated protein B  
Putative beta-actin-like 
protein 3  
Pulmonary surfactant-
associated protein B  
4 Putative beta-actin-like 
protein 3  
Serum albumin  Serum albumin  Serum albumin  
5 Serum albumin  Beta-actin-like protein 2  Moesin  Annexin A2  
6 Pulmonary surfactant-
associated protein B  
Moesin  Annexin A2  Moesin  
7 Annexin A2  POTE ankyrin domain 
family member E  
Alpha-enolase  Ig kappa chain C region  
8 Moesin  Annexin A2  Beta-2-glycoprotein 1  Ig gamma-1 chain C region  
9 Elongation factor 2  Ig gamma-1 chain C region  Ig gamma-1 chain C region  Alpha-enolase  
10 Keratin_ type II cyt Ig kappa chain C region  Ig alpha-1 chain C region  Ig lambda-1 chain C regions  
Table 3: Top 10 Proteins on cPS Particles. Top 10 most abundant proteins at each time point for cPS 
particles. Proteins with a grey back ground were identified at all time points. 
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Figure Captions: 
Figure 1: The effect of nanoparticles on mitochondrial activity. Particles were either prior incubated 
in BALF (black circles) or applied directly (white circles) to A549 cells in serum free media for 24 
hours and assessed by the MTT assay. (A) aPS particles, (B) cPS particles, (C) uPS particles and (D) 
TiO2 particles. N=3 independent experiments, each performed in triplicate. Mean ± standard 
deviation. *P<0.05, **P<0.01, ***P<0.001 (T-test, difference from untreated). 
Figure 2: Proteins bound over time between aPS and cPS particles. (A) The number of identified 
proteins bound to aPS particles over four time points. (B) The number of identified proteins bound 
to cPS particles over four time points. (C and D) Heat maps showing the concentration of quantified 
proteins that were common to each time point for aPS and cPS respectively. Each protein was 
normalised by Z-score and clustered by non-hierarchical clustering. Uniprot accession numbers for 
each protein are given at the side and protein names are listed in supplementary file SF1 & SF2. 
*P<0.05 difference between any two time points.  
Figure 3: The distribution of proteins in BALF, ordered by abundance. Red points represent proteins 
that are amongst the top 20 protein eluted from the particle after incubation in BALF for (A) cPS and 
aPS over time and (B) all particles after 1 hour incubation in BALF. Since not all proteins that were 
detected on the particles were identified in BALF, not all top 20 proteins are depicted. Uniprot 
accession numbers for each red point are given and protein names are listed in supplementary file 
SF4. 
Figure 4: Distribution of physiochemical characteristics of corona proteins. (A) isoelectric point, (B) 
molecular weight, (C) Grand Average of Hydropathy (GRAVY), (D) aromatic index, (E) % of predicted 
α-helix or (F) % of predicted β-sheet. Values were weighted by protein abundance. aPS and cPS 
particles were incubated in BALF for the time shown. uPS and TiO2 particles were incubated in BALF 
for 60 minutes. 
Figure 5: Non-hierarchical fuzzy clustering of proteins bound to aPS (A) and cPS (B) over time and 
PCA of the bound proteins physiochemical properties, coloured by cluster (C-D). Each particle was 
clustered into four groups, the degree of membership to each group is shown colourmetrically. For 
PCA analysis, blue (cluster 1), green (cluster 2), purple (cluster 3), orange (cluster 4). 
Figure 6: The distribution of the abundance of proteins for each particle corona. aPS and cPS 
particles were incubated for the time shown on the x-axis whereas uPS and TiO2 were incubated in 
BALF for 60 minutes only. 
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 Supplementary material 
Particle Media Z-Average 
(nm) 
Poly Dispersity 
Index 
aPS 
H2O 174.5 ± 0.04 0.17 ± 0.04 
PBS 181.17 ± 7.19 0.19 ± 0.03 
cPS 
H2O 82.77 ± 0.43 0.05 ± 0.01 
PBS 83.76 ± 4.55 0.05 ± 0.04 
uPS 
H2O 111.5 ± 11.42 0.15 ± 0.03 
PBS 151.7 ± 6.89 0.18 ± 0.03 
TiO2 
H2O 131 0.211 
PBS 255.9 0.158 
Media 
Only 
H2O 0.02 0.03 
PBS 631.5 0.67 
 
Supplementary Table ST1: Z-average and poly-dispersity index values from dynamic light scattering 
of 100nm aPS, cPS, uPS and 14nm TiO2 in H2O and phosphate buffered saline (PBS). Readings for 
media-only are also given. 
Particle Media Size TEM (nm) Size (AFM) (nm) Hydrodynamic 
Diameter (nm) 
Zeta Potential 
(mV) 
Image 
aPS 
PBS 
154.86 ± 96 
(median=101.35) 
78.65 ± 8.82 115.9 ± 7.89 -11.5 ± 1.81 
 BALF 293.14 ± 383.59 88.08 ± 11.33 - - 
 
cPS 
 
PBS 69.5 ± 4.6 55.31 ± 8.06 89.26 ± 4.43 -19.73 ± 1.25 
 
BALF 75.7 ± 6.9 56.1 ± 5.4 - - 
uPS 
PBS 77.7 ± 11.7 65.27 ± 6.95 90.53 ± 8.06 -17.07 ± 0.90 
 
BALF 78 ± 24.7 81.14 ± 6.88 - - 
TiO2 
PBS 14.09 ± 7.26 - 183 (n=1) -22.7 (n=1) 
 
BALF 
76 ± 134.9 
(median=37) 
- - - 
Supplementary Table ST2: Size of the particles was determined in either PBS or BALF by three 
different methods. Size determined from TEM and AFM is averaged from 100 particles. 
Hydrodynamic diameter was taken in triplicate (unless otherwise stated) in PBS only and the 
‘Number’ value is reported. All values are mean ± standard deviation. – sample measurement not 
performed. TEM images of particles incubated in PBS are presented for an idea of particle shape and 
are not to scale. 
 
Supplementary File SF1: Excel sheet: Summary of proteins detected bound to aPS particles at 
different time points. Raw data and normalised data. 
Supplementary File SF2. Excel sheet: Summary of proteins detected bound to cPS particles at 
different time points. Raw data and normalised data. 
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Supplementary File SF3. Excel sheet: Summary of proteins detected bound to particles following 60 
minute incubations. Raw data and normalised data. 
Supplementary File SF4. Excel sheet: The BALF Proteome. Rank ordered by proteins identified in 
human bronchoalveolar lavage fluid. 
 
 Supplementary figure legends: 
Supplementary figure S1: (A) The protein concentration in 10 consecutive washes was determined 
by BCA assay by washing in 200 µL and using 12.5 µL of each wash for BCA assay. The BCA analysis of 
the washes showed a sharp reduction in the bound proteins after 2 washes, dropping to sub-
detectable levels after 4 washes. (B) This was further corroborated by a SDS PAGE analysis using 10 
µL of the first 5 washes and for the cPS particles. Therefore, 5 washes were performed on the 
particles prior to analysis of the corona in combination with increasing the wash volume to 1 mL per 
wash to ensure only bound proteins were left on the particles. M= marker, with their respective Mw 
given (kDa). 1-5 = washes. B = BALF (for comparison). 
 
Supplementary figure S2: The number of protein molecules per particle, calculated from their size as 
determined hydrodynamic diameter for polystyrene and TEM for TiO2 particles. (A) Change in the 
number of proteins bound to aPS (grey line) and cPS (black line) over time. Dotted lines of the same 
colour represent the mean value across all time points. (B) The number of proteins molecules bound 
to each particle type after 60 minutes incubated (grey line, overall mean number of bound proteins). 
P-values are given when P<0.05 (T-Test). N=3 independent experiments, mean ± standard deviation. 
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